Our Scientific Advisory Committees include a consumer representative to ensure research aligns with patient needs and perspectives.
Read what Murray Turner, CEO of Psoriasis Australia, has to say about the Australasian Dermatology Registry.
THE AUSTRALIAN DERMATOLOGY REGISTRY – A PATIENT PERSPECTIVE
By Murray Turner
CEO of Psoriasis Australia
Being a patient diagnosed with psoriasis and CEO of Psoriasis Australia, I am often frustrated with the lack of accurate, comprehensive and up-to-date information on psoriasis in Australia. Far too often I am unable to provide key decision makers with a true snapshot of the burden of psoriasis in Australia. This therefore has an impact on our advocacy efforts in gaining access to new treatments sooner or lobbying for more dermatologists.
The Australian Dermatology Registry (ADR) is an important initiative that will improve the care and treatment of patients with psoriasis for several reasons. It will:
- Improve Access to Care – it will allow patients to experience more personalised care due to the ability to track the effectiveness of various treatments over time. By utilising data from the registry, healthcare professionals can more accurately identify which treatments are likely to be most effective based on a patient’s specific characteristics, therefore, reducing the time spent on ineffective therapies.
- Support Research and Policy Development – it will provide researchers and policymakers with access to up-to-date and reliable data, that can be used to inform healthcare policies, allocate resources, and guide research efforts.
- Raise Awareness – the centralised data repository will allow Psoriasis Australia to better inform the public about the burden of psoriasis and associated comorbidities, therefore reducing the stigma and promoting a better understanding of the disease.
Overall, the ADR is a critical initiative for improving the understanding of psoriasis and the burden of the disease on those in Australia. If your clinic has not yet registered to be part of the registry, I implore you to reach out to the ADR, so you and your patients can help improve the care, treatment and lives of those impacted by psoriasis.